Improved models for pharmacological null experiments: Calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines

Neuropharmacology

Volumn 35, Issue 5, 1996, Pages 549-570

  Mak, Chun K ^a,d   Avalos, Melva ^a,d   Randall, Patrick K ^a,d   Kwan, Sau Wah ^a   Abell, Creed W ^a   Neumeyer, John L ^b   Whisennnand, Richard ^c   Wilcox, Richard E ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Research Biochemicals International   (United States)

^c McCallum High School   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Affinity; CAMP; Cell culture; Clonal cell line; Dopamine; Efficacy; Recombinant receptor; Stable expression

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 BROMO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; CYCLIC AMP; DOPAMINE; DOPAMINE D1A RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FENOLDOPAM; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; PARTIAL AGONIST; RBI 226; RECEPTOR RESERVE; RECEPTOR SUBTYPE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ARTICLE; CELL CLONE; COMPUTER SIMULATION; CONTROLLED STUDY; CURVE FITTING; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOMA CELL; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; RECOMBINANT DNA TECHNOLOGY; TECHNIQUE;

EID: 0030152114     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/0028-3908(96)84625-9     Document Type: Article

References (68)

1. Agarwal A., Taylor E. 3D QSAR for intrinsic activity of 5-HT1A receptor ligands by the method of comparative molecular field analysis. J. Comp. Chem. 14:1993;237-245.
2. Ausubel F., Brent R., Kingston R., Moore D., Seidman J., Smith J.A. and Struhl K. (1992) short Protocols in Molecular Biology: A Compendium of Methods From Current Protocols in Molecular Biology (Second edition), pp. 9-1-9-30. John Wiley, New York.
3. Bates M.D., Caron M.G., Raymond J.R. Densensitization of DA1 dopamine receptors coupled to adenylyl cyclase in opossum kidney cells. Am. J. Physiol. 260:1991;F937-F945.
4. Benovic J.L., Strasser R.H., Caron M.G., Lefkowitz R.J. β-Adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc. Natn. Acad. Sci. U.S.A. 83:1986;2797-2801.
5. Bouvier M., Hausdorff W.P., de Blasi A., O'Dowd B.F., Kobilka B.K., Caron M.G., Lefkowitz R.J. Removal of phosphorylation sites from the β2-adrenergic receptor delays onset of agonist-promoted desensitization. Nature. 333:1988;370-373.
6. Caron M.G. and Lefkowitz R.J. (1993) Catecholamine receptors: structure, function, and regulation. In: Recent Progress in Hormone Research, Vol. 48, pp. 277-290. Academic Press, New York.
7. Civelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors. A. Rev. Pharmacol. Toxicol. 32:1993;281-307.
8. Cox B., Henningsen R., Spanoyannis A., Neve R.L., Neve K.A. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. J. Neurochem. 59:1992;627-635.
9. Dearry A., Gingrich J.A., Falardeau P., Fremeau R.T. Jr., Bates M.D., Caron M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 347:1990;72-76.
10. DeLean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 235:1978;E97-E102.
11. DeLean A., Munson P.J., Guardabasso V. and Rodbard D. (1992) A user's guide to ALLFIT: simultaneous fitting of families of sigmoidal dose-response curves using the four-parameter logistic equation. Laboratory of Theoretical and Physical Biology, National Institute of Child Health and Human development, National Institutes of Health, Bethesda, MD 20892, U.S.A.
12. DeLean A., Stadel J., Lefkowitz R. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 55:1980;7108-7117.
13. Eglen R., Whiting R. Estimation of apparent agonist affinity constants using desensitization of the ileal muscarinic receptor. J. Pharmacol. Exp. Ther. 240:1987;404-409.
14. Ehlert F. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Molec. Pharmacol. 33:1988;187-194.
15. Enz A., Goldstein M., Meller E. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum. Molec. Pharmacol. 37:1990;560-565.
16. Farndale R., Allan L. and Martin R. (1992) Adenylate cyclase and cAMP. In: Signal Transduction: A Practical Approach (Milligan G., Ed.), pp. 75-104. Oxford University Press, New York.
17. Furchgott R.F. (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Advances in Drug Research, Vol. 3 (Harner N.J. and Simmons A.B., Eds), pp. 21-55. Academic Press, New York.
18. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. A. Rev. Neurosci. 16:1993;299-321.
19. Grenader A., Healy D. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells. J. Pharmacol. Exp. Ther. 258:1991;193-198.
20. Hamblin M., Creese I. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes. Molec. Pharmacol. 21:1982;44-51.
21. Hartmann M., Baldessarini R.J., Kula N., Huston-Lyons D., Baindurand N., Neumeyer J.L. Potency of D1 receptor affinity ligands with alkylating moieties. Soc. Neurosci. Abstr. 18:1992;275.
22. Hausdorff W.P., Campbell P.T., Ostrowski J., Yu S.S., Caron M.G., Lefkowitz R.J. A small region of the β-adrenergic receptor is selectively involved in its rapid regulation. Proc. Natn. Acad. Sci. U.S.A. 88:1991;2979-2983.
23. Herepath M.L., Bradley K.J. Affinities of full agonists for cardiac β-adrenoceptors calculated by use of in vitro desensitization. Naunyn-Schmiedeberg's Arch. Pharmacol. 341:1990;525-533.
24. Herndon H. N-Ethylmaleimide inactivates adenylate cyclase-coupled but not presynaptic striatal D2 receptor systems. Eur. J. Pharmacol. 154:1988;115-116.
25. +-ATPase activity through protein kinase A. Molec. Pharmacol. 43:1992;281-285.
26. Imai S.I., Kitamura Y., Nomura Y. Different effects of N-ethylmaleimide on the binding characteristics of 5-hydroxytryptamine receptor subtypes in rat brain membranes. Neurochem. Int. 18:1991;331-339.
27. a): Directly fitting the postinactivation concentration-response curve to a nested hyperbolic equation. J. Pharmacol. Exp. Ther. 249:1989;61-69.
28. 5 receptor. J. Receptor Res. 13:1993;573-590.
29. Kenakin T.P. (1993) Pharmacologic Analysis of Drug-receptor Interaction (Second edition). Raven Press, New York, pp. 1-468.
30. Kenakin T. The classification of drugs and drug receptors in isolated tissues. Pharmacol. Rev. 36(3):1984;165-222.
31. Kenakin T., Bond R., Bonner T. II. Definition of pharmacological receptors Pharmacol. Rev. 44(3):1992;351-362.
32. Knuth, D. (1981) The Art of Computer Programming Vol 2: Seminumerical Algorithms (Second edition). Addison-Wesley, Reading, MA.
33. Lovenberg T.W., Roth R.H., Nichols D.E., Mailman R.B. D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors. J. Neurochem. 57:1991;1563-1569.
34. Machida C., Searles R., Nipper V., Brown J., Kozell L., Neve K. Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene. Molec. Pharmacol. 1:1992;652-659.
35. Mackay D. Agonist potency and apparent affinity: interpretation using classical and steady state ternary complex models. TIPS. 11:1990;17-22.
36. Mak C.K., Randall P.K., Avalos M., Burns S., Abell C.W., Kwan S.-W., Wilcox R.E. Dopamine agonists have two separable properties: induction of cellular response and induction of desensitization. Soc. Neurosci. Abstr. 20:1994;520.
37. Minowa M.T., Minowa T., Monsma F.J. Jr., Sibley D.R., Mouradian M.M. Characterization of the 5′ flanking region of the human D1A dopamine receptor gene. Proc. Natn. Acad. Sci. U.S.A. 89:1992;3045-3049.
38. Mishell B.B. and Shiigi S.S. (Eds) (1980) Cellular Immunology, pp. 14-18. W.H. Freeman and Co., San Francisco.
39. Monsma F.J. Jr., Mahan L.C., McVittie L.D., Gerfen C.R., Sibley D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natn. Acad. Sci. U.S.A. 87:1990;6723-6727.
40. Nantel F., Marullo S., Krief S., Strosberg A.D., Bouvier M. Cell-specific down-regulation of the beta3-adrenergic receptor. J. Biol. Chem. 269:1994;13148-13155.
41. Neumeyer J.L., Kula N.S., Baldessarini R.J., Baindur N. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R(+) and S(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1-H-3-benzazepine and its 6-bromo analogue. J. Med. Chem. 35:1992;1466-1471.
42. Norusis M.J. (1990) SPSS: Statistical Package for the Social Sciences. SPSS, Inc., Chicago, Illinois.
43. O'Boyle K., Waddington J. Agonist and antagonist properties of 1-phenyl-3-benzazepine analogues at the D1 dopamine receptor. Br. J. Pharmacol. 82:1988;132P.
44. O'Dowd B.F. Structures of dopamine receptors. J. Neurochem. 60:1993;804-816.
45. Olson M.F., Schimmer B.P. Heterologous desensitization of the human dopamine D1 receptor in Y1 adrenal cells and in a desensitization-resistant Y1 mutant. Molec. Endocrin. 6:1992;1095-1102.
46. Parker R., Waud D.R. Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists J. Pharmacol. Exp. Ther. 177:1971;1-12.
47. Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T. (1988) Numerical Receipes in C: The Art of Scientific Computing. Cambridge University Press, Cambridge.
48. Ratkowsky D. (1983) Non-linear Regression Modeling: A Unified Practical Approach. Marcel Dekker, New York.
49. Ruffolo R.R. Jr. Important concepts of receptor theory. J. Autonom. Pharmacol. 2:1982;277-295.
50. Ruffolo R.R. Jr., Rosing E., Waddell J. Receptor interactions of imidazolines. I. Affinity and efficacy for alpha adrenergic receptors in rat aorta J. Pharmacol. Exp. Ther. 209:1979;429-436.
51. Ruffolo R.R. Jr., Waddell J. Aromatic and benzylic hydroxyl substitution of imidazolines and phenthylamines: differences in activity at alpha-1 and alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther. 224:1983;559-566.
52. Saller C.F., Kreamer L., Adamovage L., Salama A.I. Dopamine receptor occupancy in vivo: measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Life Sci. 45:1989;917-929.
53. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta-2-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 268:1993;4625-4636.
54. Schwinn D.A., Caron M.G. and Lefkowitz R.J. (1992) The β-adrenergic receptor as a model for molecular structure-function relationships in G-protein-coupled receptors. In: The Heart and Cardiovascular System (Fozzard H.A. et al., Eds), 2nd edition, pp. 1657-1684. Raven Press, New York.
55. Seeman P. Dopamine receptor sequences - therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
56. Sibley D.R., Monsma F.J. Jr. Molecular biology of dopamine receptors. TIPS. 13:1992;61-69.
57. Sunahara R.G., Niznik H.B., Weiner D.M., Stormann T.M., Brann M.R., Kennedy J.L., Gelernter J.E., Rozmahel R., Yang Y., Israel Y., Seeman P., O'Dowd B.F. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature. 347:1990;80-83.
58. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H.M., Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 350:1991;614-619.
59. Tallarida R.J. Pharmacologic methods for identification of receptors. Life Sci. 43:1988;2169-2176.
60. Tiberi M., Jarvie K.R., Silvia C., Falardeau P., Gingrich J.A., Godinot N., Bertrand L., Yang-Feng T.L., Fremeau R.T. Jr., Caron M.G. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc. Natn. Acad. Sci. U.S.A. 88:1991;7491-7495.
61. Unnerstall J.R. (1990) Computer-assisted analysis of binding data. In: Methods in Neurotransmitter Receptor Analysis (Yamamura H.I., Enna S.J. and Kuhar M.J., Eds), pp. 37-68. Raven Press, New York.
62. Whaley B., Yuan N., Birnbaumer L., Clark R., Barber R. Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Molec. Pharmacol. 45:1994;481-489.
63. Wilcox R.E. and Gonzales R.A. (1995) Introduction to neurotransmitters, receptors, signal transduction, and second messengers. In: Textbook of Psychopharmacology (Nemeroff C.B. and Schatzberg A.F., Eds.), pp. 1-44. American Psychiatric Press, Washington, D.C.
64. Wilcox R.E., Mak C.K., Avalos M.N., Randall P.K., Kwan S.-W., Abell C.W., Neumeyer J. Relative intrinsic efficacy and functional affinity constants of drugs in C6 glioma cells stably expressing the D1A dopamine receptor. Soc. Neurosci. Abstr. 19:1993;75.
65. Wilcox R., Brusniak M.-Y., Pearlman R. CoMFA-based prediction of drug affinities at recombinant D1A dopamine receptors. Soc. Neurosci. Abstr. 20:1994;521.
66. Yu S., Lefkowitz R., Hausdorff W. β-adrenergic receptor sequestration: a potential mechanism of receptor resensitization. J. Biol. Chem. 268:1993;337-341.
67. Zhong H., Minneman K. Coexisting beta-1 and beta-2-adrenergic receptors with differential receptor reserves in rat C6 glioma cells. J. Pharmacol. Exp. Ther. 272:1995;1088-1094.
68. 1 dopamine receptors. Nature. 347:1990;76-80.